Results 51 to 60 of about 1,329,719 (361)
Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice [PDF]
, 2009 The SpAs are a group of overlapping, chronic, inflammatory rheumatic diseases including AS, a chronic inflammatory disease primarily affecting the SI joints.
Elewaut, Dirk, Matucci-Cerinic, Marco
core +1 more source
BMC Cardiovascular Disorders, 2022 Background In a Phase I study treatment with the serum amyloid P component (SAP) depleter miridesap followed by monoclonal antibody to SAP (dezamizumab) showed removal of amyloid from liver, spleen and kidney in patients with systemic amyloidosis.
A. Wechalekar +24 more
semanticscholar +1 more source
Catastrophic Cardiac Amyloidosis [PDF]
Cardiology Research and Practice, 2011 We report a case of a 61-year-old patient presenting with cardiogenic shock. His echocardiogram suggested typical features of cardiac amyloidosis. This case demonstrates that cardiac amyloidosis can present acutely and may be catastrophic.
Prashanth Panduranga, Mohammed Mukhaini
openaire +4 more sources
Technetium-99m pyrophosphate cardiac SPECT in endomyocardial biopsy negative cardiac amyloidosis
Radiology Case Reports, 2018 Cardiac amyloidosis is an under-appreciated cause of heart failure. Establishing a diagnosis is important because traditional heart failure treatment regimens can worsen left ventricular failure in this disease. Endomyocardial biopsy is the gold standard
Martin Krupa, MD +3 more
doaj +1 more source
Dataset on the use of 3D speckle tracking echocardiography in light-chain amyloidosis [PDF]
, 2018 The dataset presented in this article is related to the research article entitled “Biventricular assessment of light-chain amyloidosis using 3D speckle tracking echocardiography: Differentiation from other forms of myocardial hypertrophy” (Vitarelli et ...
Antonio Vitarelli +10 more
core +2 more sources
Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.
Circulation Research, 2021 Often considered a rare disease, cardiac amyloidosis is increasingly recognized by practicing clinicians. The increased rate of diagnosis is in part due the aging of the population and increasing incidence and prevalence of cardiac amyloidosis with ...
J. Griffin, H. Rosenblum, M. Maurer
semanticscholar +1 more source
Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds [PDF]
, 2018 PURPOSE: 18F-Florbetapir has been reported to show cardiac uptake in patients with systemic light-chain amyloidosis (AL). This study systematically assessed uptake of 18F-florbetapir in patients with proven systemic amyloidosis at sites outside the heart.
Burniston, M +8 more
core +1 more source
Re-Definition of the Epidemiology of Cardiac Amyloidosis
Biomedicines, 2022 The epidemiology of cardiac amyloidosis (CA), traditionally considered a rare and incurable disease, has changed drastically over the last ten years, particularly due to the advances in diagnostic methods and therapeutic options in the field of ...
M. Rossi +9 more
semanticscholar +1 more source
Journal of the Belgian Society of Radiology, 2015 The frequency of cardiac involvement varies among other types of amyloidosis. Cardiac amyloidosis leads to systolic and diastolic dysfunction with symptoms of heart failure. Cardiac magnetic resonance (CMR) findings are helpful in supporting the diagnosis of amyloid cardiomyopathy.
Lu, P., Van Acker, H., Waer, P.
openaire +4 more sources
ESC Heart Failure, 2021 Aims As evidenced by scintigraphy imaging, the prevalence of transthyretin (TTR) cardiac amyloidosis in heart failure patients with preserved ejection fraction (HFpEF) and left ventricular hypertrophy (LVH) ranges between 13% and 19%.
Ana Devesa +10 more
doaj +1 more source